Clinical trial
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-WEEKLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY WITH OR WITHOUT TYPE 2 DIABETES (VESPER-OA 2)
NCT07915609 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-WEEKLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY WITH OR WITHOUT TYPE 2 DIABETES (VESPER-OA 2)
- Lead sponsor
- Pfizer
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- October 26, 2026
- Completion date
- October 30, 2028
- Enrollment
- 756 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
diabetes melliuts, type 2, knee osteoarthritis, obesity, overweight and/or obesity
Arms
As registered; 4 arms.
-
Placebo
Placebo
-
Arm 1: Berobenatide Once Weekly
Berobenatide Once Weekly
-
Arm 2: Berobenatide Once Weekly
Berobenatide Once Weekly
-
Arm 3: Berobenatide Once Weekly
Berobenatide Once Weekly
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale score
Lead sponsor's other trials
Pfizer, most recent start first.
+3,332 more trials See the organization page
Similar trials
Same condition (Osteoarthritis, Knee) and phase, most recent start first.
+210 more trials See the condition page